C&EN White Papers | Orphan drug development – A pragmatic approach to developing a rare disease drug

Orphan drug development – A pragmatic approach to developing a rare disease drug

Brought to you by Curia Global

Overview

Most medicines in development today target diseases affecting large sections of the global population. However, we are now slowly beginning to see a rise in interest around developing "orphan drugs," which are pharmaceutical agents intended to treat rare diseases. The global orphan drug market is projected to increase at a compound annual growth rate (CAGR) of 12.10% between 2017 and 2025 and is expected to achieve a net valuation of US$318.5 billion by the end of 2025.

As more drug developers become interested in sponsoring an orphan drug program, it's important to understand the challenges associated with developing these drugs on an expedited timeline, as well as ways to mitigate these challenges.

Key Objectives:

Download our white paper for insights into:

The global orphan drug market
Challenges in orphan drug development
Considerations associated with the expedited development of orphan drugs
How to optimally position your organization to address relevant constraints

Brought to you by:

This content was created by Curia Global, without editorial input from the C&EN Media Group. For more information on C&EN's custom products, visit our C&EN Media Kit.

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

Area of Interest*

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.